This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Talon Therapeutics, Inc. Reports Fourth Quarter And Year End 2010 Financial Results

Total operating expenses for the three months ended December 31, 2010, were $6.5 million, compared with $5.4 million for the three months ended December 31, 2009. Research and development expenses were $5.2 million for the three months ended December 31, 2010, compared with $4.0 million for the three months ended December 31, 2009. General and administrative expenses were $1.3 million for the three months ended December 31, 2010, compared with $1.4 million for the three months ended December 31, 2009.

As of December 31, 2010, the Company had cash, cash equivalents and available-for-sale securities of $22.6 million. Cash used in operations was $5.1 million for the three months ended December 31, 2010.

The per share results for all periods have been adjusted to reflect the impact of the Company's 1-for-4 reverse stock split that occurred at the close of business on September 10, 2010.

Twelve Months Ended December 31, 2010 Financial Results

For the twelve months ended December 31, 2010, the Company reported a net loss of $26.0 million and deemed dividends on preferred stock of $32.3 million, which when combined, resulted in a net loss applicable to common stockholders of $58.3 million, or $2.81 per share. The deemed dividends on preferred stock contributed $1.56 per share to the total net loss applicable to common stockholders for the twelve months ended December 31, 2010. This compares with a net loss of $24.1 million, or a loss per share of $2.27, for the twelve months ended December 31, 2009. There were no deemed dividends on preferred stock for the twelve months ended December 31, 2009.

Total operating expenses for the twelve months ended December 31, 2010, were $25.8 million, compared with $19.6 million for the twelve months ended December 31, 2009. Research and development expenses were $20.2 million for the twelve months ended December 31, 2010, compared with $14.7 million for the twelve months ended December 31, 2009. General and administrative expenses were $5.6 million for the twelve months ended December 31, 2010, compared with $4.9 million for the twelve months ended December 31, 2009.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,853.26 -74.94 -0.42%
S&P 500 2,083.16 -6.30 -0.30%
NASDAQ 4,926.5070 -12.82 -0.26%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs